Daily Cardiology Research Analysis
Three impactful cardiology studies stand out today: a patient-specific digital twin approach shows left atrial hemodynamics modulate the efficacy of factor XI/XII inhibition; normothermic regional perfusion from donation after circulatory death yields heart transplant outcomes comparable to brain-dead donors; and cumulative duration of diabetes and hypertension independently predicts worse long-term outcomes after CABG.
Summary
Three impactful cardiology studies stand out today: a patient-specific digital twin approach shows left atrial hemodynamics modulate the efficacy of factor XI/XII inhibition; normothermic regional perfusion from donation after circulatory death yields heart transplant outcomes comparable to brain-dead donors; and cumulative duration of diabetes and hypertension independently predicts worse long-term outcomes after CABG.
Research Themes
- Personalized anticoagulation via cardiovascular digital twins
- Expanding the heart transplant donor pool with DCD-NRP
- Cumulative cardiometabolic exposure shaping surgical outcomes
Selected Articles
1. Hemodynamics affects factor XI/XII anticoagulation efficacy in patient-derived left atrial models.
Using patient-specific left atrial anatomies and a 32-factor coagulation model, the authors generated spatiotemporal thrombin maps showing peaks in the left atrial appendage. Patients stratified by left atrial appendage thrombin dynamics required differing intensities of factor XI/XII inhibition to suppress thrombin growth, with high-risk hemodynamics (slow flow, high residence time) requiring stronger inhibition.
Impact: This work pioneers a cardiovascular digital twin linking patient-specific left atrial flow to the pharmacodynamic efficacy of factor XI/XII inhibition, a class under active clinical development. It provides a mechanistic basis for tailoring anticoagulation beyond one-size-fits-all strategies.
Clinical Implications: If prospectively validated, patient-specific hemodynamic profiling could guide dosing and selection of factor XI/XII inhibitors in atrial fibrillation, particularly in patients with adverse left atrial appendage flow who may require stronger inhibition.
Key Findings
- Patient-specific simulations across 13 anatomies produced thrombin maps peaking in the left atrial appendage.
- Left atrial appendage thrombin dynamics enabled classification into no, moderate, and high thromboembolic risk groups.
- High-risk hemodynamics (slower LAA flow, higher residence time) required stronger factor XI/XII inhibition to prevent thrombin growth.
- A novel multi-fidelity modeling approach accelerated computations by ~100-fold, enabling 247 simulations.
Methodological Strengths
- Integration of 4D CT-derived patient-specific geometries with a detailed 32-factor coagulation network.
- Systematic exploration of pharmacologic inhibition levels across diverse hemodynamics using accelerated multi-fidelity modeling.
Limitations
- Small cohort (n=13) without prospective linkage to clinical thromboembolic events.
- In silico pharmacology assumptions; no direct drug dosing or bleeding outcome data.
Future Directions: Prospective validation against clinical outcomes; model-guided dosing trials of factor XI/XII inhibitors; incorporation of patient-specific blood rheology and atrial function dynamics.
BACKGROUND AND OBJECTIVE: Atrial fibrillation (AF) is a common arrhythmia that disrupts blood circulation in the left atrium (LA), causing stasis in the left atrial appendage (LAA) and increasing thromboembolic risk. In patients at sufficiently high risk, anticoagulation is indicated. This benefit may be counterbalanced by an increased risk of bleeding. Novel anticoagulants under development, such as factor XI/XII inhibitors, may be associated with a lower bleeding risk.
2. Normothermic regional perfusion in donation after circulatory death compared with brain dead donors: Single-center cardiac allograft outcomes.
In 415 heart transplant recipients (275 DBD, 140 DCD-NRP), propensity-matched analyses showed no differences in severe primary graft dysfunction, need for mechanical circulatory support, right heart dysfunction, vasoactive inotropic scores, 30-day mortality, or 1- and 3-year survival between DCD-NRP and DBD allografts.
Impact: Findings support clinical equivalence of DCD-NRP and DBD heart allografts, potentially expanding the donor pool without compromising outcomes.
Clinical Implications: Centers can consider DCD-NRP donors as equivalent to DBD for recipient outcomes, supporting wider adoption of NRP to increase transplant availability.
Key Findings
- Among 415 recipients, no differences were observed in severe primary graft dysfunction, mechanical circulatory support, right heart dysfunction, vasoactive inotropic scores, or 30-day mortality between DCD-NRP and DBD groups after propensity matching.
- No differences in 1- and 3-year survival between DCD-NRP and DBD allografts.
- Results suggest DCD-NRP donors are equivalent to DBD donors in short- and mid-term outcomes.
Methodological Strengths
- Propensity score matching to balance baseline characteristics.
- Comprehensive assessment of early and intermediate outcomes including survival analyses.
Limitations
- Single-center retrospective design with potential selection bias.
- Limited detail on donor and procurement variables in the abstract (e.g., warm ischemia times).
Future Directions: Multicenter prospective registries and standardized NRP protocols to confirm generalizability and assess long-term outcomes.
OBJECTIVE: We sought to provide a single-center analysis of our normothermic regional perfusion (NRP)-recovered donation after circulatory death (DCD) heart transplant outcomes compared with a historical control group of donors of donation after brain death (DBD). We hypothesized that postoperative short-term outcomes and long-term survival trends are comparable in DCD-NRP and DBD cardiac allografts. METHODS: All adult heart-only transplants performed at our institution between January 2020 and June 2024 were retrospectively reviewed.
3. The Association Between Diabetes and Hypertension Time Course, Their Cumulative CoExposure, and PostCoronary Artery Bypass Graft Outcomes.
In 10,803 CABG patients followed a median of 111.3 months, longer duration of diabetes and hypertension was associated with stepwise increases in all-cause mortality and MACCE. Risks were higher when both conditions coexisted, and the association of shorter diabetes duration attenuated in nonhypertensive patients.
Impact: By quantifying exposure duration effects, this study refines risk stratification after CABG beyond binary diagnoses, informing tailored prevention and follow-up strategies.
Clinical Implications: Incorporating duration of diabetes and hypertension into risk models may improve prognostication after CABG and identify patients needing intensified secondary prevention.
Key Findings
- Diabetes duration showed a graded association with outcomes: all-cause mortality HR rose from 1.37 (<5y) to 1.91 (≥10y) versus non-diabetic; MACCE HR from 1.23 to 1.59.
- Hypertension duration also increased risk: all-cause mortality HR 1.38 to 1.51; MACCE HR 1.27 to 1.39 across duration categories.
- Risk amplification was more pronounced when diabetes coexisted; shorter diabetes duration associations were nonsignificant in nonhypertensives.
Methodological Strengths
- Large sample size (n=10,803) with long median follow-up (111.3 months).
- Stratified Cox models assessing duration categories and co-exposure interactions.
Limitations
- Single-center retrospective cohort with potential residual confounding.
- Exposure duration derived from clinical records may be subject to misclassification; no external validation.
Future Directions: Validate duration-based risk metrics externally and integrate into surgical risk calculators; test whether intensified secondary prevention guided by duration reduces post-CABG events.
BACKGROUND: The association between patient outcomes and cumulative effects of cardiovascular risk factors over time is recognized but poorly quantified. This study quantitatively addressed the impact of diabetes and hypertension duration, and their combined effect, on postcoronary artery bypass grafting (CABG) outcomes. METHODS: This single-center cohort study included patients who underwent coronary angiography followed by isolated CABG (n = 10,803, median follow-up: 111.3 months) from 2007 to 2017. Study outcomes comprised all-cause mortality and major adverse cardio-cerebrovascular events (MACCE).